AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02374437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
Study NCT04505995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine and homoharringtonine
Description: Concommitant use of azacitidine and homoharringtonine
Study NCT03318211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Intravenous ampules of MgSo4 was given to only to control group after delivery
Study NCT03227484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25mg
Description: Once daily over 8 weeks
Study NCT03227484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Once daily over 8 weeks
Study NCT03171168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AposTherapy
Description: AposTherapy is a home-based exercise program utilizing footwear that causes exercise with normal daily activity that may significantly improve function in patients with knee pain in general, and specifically knee osteoarthritis (OA).
Study NCT03171168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: Up to 20 sessions of traditional physical therapy
Study NCT03749460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03749460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03749460 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT00277589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxin-Na
Description: 1 tablet 30 minutes before breakfast
Study NCT00277589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine-Na + iodide
Description: 1 tablet 30 minutes before breakfast
Study NCT00277589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodide
Description: 1 tablet 30 minutes before breakfast
Study NCT00277589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet 30 minutes before breakfast
Study NCT00389090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide and O6-Benzylguanine
Description: O6BG + Temozolomide
Study NCT01248520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: influenza and general health information
Description: Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver. These messages will contain general health information as well as information regarding influenza and the importance of vaccination during pregnancy.
Study NCT01248520 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: general health information
Description: Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver.
Study NCT03656458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm Up
Description: 10 low jumps 5 Illiopoase Stretches 5 L/L Abductor Stretches 10 Trunk rotations 10 Should Circumduction Clock wise/Counter clockwise 10 Cervical Rotations Clockwise/Counter Clockwise
Study NCT03656458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm Up
Description: 10 low jumps 5 Illiopoase Stretches 5 L/L Abductor Stretches 10 Trunk rotations 10 Should Circumduction Clock wise/Counter clockwise 10 Cervical Rotations Clockwise/Counter Clockwise
Study NCT03656458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Balance Training
Description: Internal Protuberances:~1. Looking up/Looking down/looking over the shoulder (Rt. /Lt.) 10 Reps Each~2. Looking behind over the shoulder (Rt. /Lt.)10 Reps~3. Looking Up with overhead Upper Limb Flexion. 5 Reps~4. Reaching out of Base of support (Rt. /Lt. / midline Cross) 10 Reps Each~5. Side to Side weight Shifting 10 Reps~6. Standing on toes/Heels 10 Reps each~External Protuberance:~1. Tuck forward/ Backward/ Sideways(Rt. /Lt.) 10 reps Each~2. Bosu Ball Training
Study NCT03656458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodex Balance Training
Description: Biodex Balance Training Using Biodex Balance System SD
Study NCT01194882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUMAN INSULIN (BIOSYNTHETIC)
Description: Pharmaceutical form: solution for infusion Route of administration: Intraperitoneal use Dose regimen: 400 IU/ml
Study NCT01194882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insuplant
Description: Pharmaceutical form:solution for infusion Route of administration: Intraperitoneal use~Dose regimen:
Study NCT00128245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Study NCT00128245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo
Study NCT02766998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preserved umbilical vein as shunt/conduit
Description: All subjects will have umbilical vein harvested and stored for use in first cardiac surgery requiring shunt or conduit.
Study NCT04376229 — intervention group
Intervention type: OTHER
Intervention: Registry
Description: Registry of cancer patients who receive proton radiation therapy
Study NCT04239456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RehaCom (software)
Description: RehaCom software has gamified, interactive modules that will help participants practice the application of various memory strategies at custom, increasingly more difficult levels. Instructor will also use the software to teach and demonstrate the use of memory strategies with the domains targeted (i.e., list learning, remembering written/verbal information, and memory for names/faces).
Study NCT00884650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral analgesic
Description: per clinical standard of care
Study NCT00884650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous analgesic per pump
Description: per clinical standard of care
Study NCT03831854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine 300 MG
Description: 300 mg of oral Lamotrigine. One of the key studies in this area was reported at the Society of Neuroscience meeting in 1997 and later published in the Archives of General Psychiatry. This study reported that, in healthy subjects 300 mg oral lamotrigine significantly decreased ketamine-induced perceptual abnormalities as assessed by the Clinician-Administered Dissociative States Scale (P\<.001).31 Furthermore lamotrigine increased the immediate mood-elevating effects of ketamine (P\<.05).
Study NCT03831854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg of oral Placebo
Study NCT03831854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: 1mg/kg bolus at induction followed by 5 microgram/kg/min infusion till the end of the surgery
Study NCT03831854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 1mg/kg bolus at induction followed by 5 microgram/kg/min infusion till the end of the surgery
Study NCT00370110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itopride 100 mg
Description: 100 mg three times daily
Study NCT00370110 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study NCT00370110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itopride 200 mg
Description: 200 mg three times daily
Study NCT01542346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subcutaneous adaption
Study NCT02674269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 IU of BotuGelTM (60ml)
Description: One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
Study NCT02674269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 IU of BotuGelTM (60ml)
Description: One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
Study NCT02674269 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TC-3 Gel
Description: Intravesical instillation of 60 ml TC-3 gel
Study NCT01705405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Software for acquiring ultrasound and endoscopic images
Description: Use of a medical device to acquire ultrasound and endoscopic images
Study NCT01519778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR701 FA
Description: 1 tablet 200 mg once daily
Study NCT02775838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: perioperative application of Indocyanine green (ICG)
Study NCT01913899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational/ physical therapy
Study NCT01913899 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational/ physical therapy
Study NCT01913899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: - Intervention group: treatment sessions of 60 minutes with mirror therapy over a period of 14 days starting directly post surgical (24-48 hours)
Study NCT02272361 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: laparoscopic sacrocolpopexy
Study NCT02272361 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: vaginal mesh surgery
Study NCT01265043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral hygiene intervention
Description: Oral health promotion intervention
Study NCT02573649 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop Stimulation on first
Description: Closed-loop Stimulation algorithm is turned on in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned off and the patient performs a second head up tilt test.
Study NCT02573649 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop Stimulation off first
Description: Closed-loop Stimulation algorithm is turned off in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned on and the patient performs a second head up tilt test.
Study NCT03845712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxecitine and doxribtimine
Description: Doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart. Doxecitine and doxribtimine is administered with food.
Study NCT02378636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 600S
Description: Monofocal Aspheric Intraocular Lens (IOL)
Study NCT04695652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901(S protein with adjuvant)
Description: Approximately 3180 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
Study NCT04695652 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MVC-COV1901(Saline)
Description: Approximately 530 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region
Study NCT02164019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: long-stem cemented hemiarthroplasty (LSCH)
Study NCT02164019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intramedullary nailing (IMN)
Study NCT02164019 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Study NCT00232219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil
Study NCT04434118 — intervention group
Intervention type: DRUG
Intervention: Traditional antirheumatic drugs
Description: Hydroxychloroqine, Methotrexate, Glucocorticoids, Leflunomide, and Sulphasalazine
Study NCT01375751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study NCT01375751 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: d by subcutaneous injection
Study NCT04739410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin Prescribing protocol: Participants were prescribed Ivermectin 12 mg per oral stat and then 12 mg per oral after 12 hours and 12 mg per oral after 24 hours and we looked at the response at day 7 on follow up in terms of improvement of symptoms like (Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue.Any side effects of the drugs were noted as well
Study NCT04739410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivermectin
Description: Ivermectin Prescribing protocol: Participants were prescribed Ivermectin 12 mg per oral stat and then 12 mg per oral after 12 hours and 12 mg per oral after 24 hours and we looked at the response at day 7 on follow up in terms of improvement of symptoms like (Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue.Any side effects of the drugs were noted as well
Study NCT02695147 — intervention group
Intervention type: PROCEDURE
Intervention: TAVI
Study NCT04310332 — intervention group
Intervention type: DRUG
Intervention: 1L-PEG
Description: The drug is 1L-PEG plus ascorbic acid (Plenvu®). It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational.
Study NCT04310332 — intervention group
Intervention type: DRUG
Intervention: 4L-PEG
Description: The drug is 4L-PEG. It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational.
Study NCT00254969 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib
Description: 0.5 mL, Im
Study NCT00899145 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04467645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reflexology
Description: Reflexology is the stimulation of the reflex points in the hands and feet by massage, designed to provide relaxation and relief in the body.
Study NCT01844726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYX-13
Description: Single injection (5 mg/kg) of GLYX-13, an NMDAR partial agonist
Study NCT01844726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single injection of placebo (saline)
Study NCT02412449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548 tablet, reference formulation given in the fasted state
Study NCT02412449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548 tablet, test formulation given in the fasted state.
Study NCT02412449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548 tablet, test formulation given in the fed state
Study NCT03021551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rainbow sensor
Description: Masimo Radical-7 and Root System with ORi parameter in all subjects are enrolled in the test group and receive an Rainbow sensor during their elective surgery.
Study NCT03792347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Arm1：Pre-operative Pembrolizumab+chemoradiotherapy
Study NCT03685682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant subunit Herpes zoster vaccine
Description: Seronegative Solid Organ Transplant patients will receive two doses of the subunit Herpes zoster vaccine at 0 and 2-6 months
Study NCT03667118 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food Supplement
Description: A powder blend of 16 common allergenic proteins (\[oat, milk, egg, sesame, wheat\] \[almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut\] \[cod, shrimp, salmon\]) combined with 400 IU of Vitamin D3
Study NCT03667118 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Food Supplement
Description: A powder blend of 16 common allergenic proteins (\[oat, milk, egg, sesame, wheat\] \[almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut\] \[cod, shrimp, salmon\]) combined with 400 IU of Vitamin D3
Study NCT00959010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 triglycerides
Description: capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA, 60mg/kg/day 3 times a day during 12 months.
Study NCT00959010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules containing middle chain triglycerides
Study NCT00872001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acadesine
Description: Acadesine 42 mg/kg diluted in normal saline to a total of 500 mL, delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 0.1 mg/kg/min (translating into 1.2 mL/min for a 500 mL solution). In addition, a 5 µg/mL cardioplegia solution of acadesine will be administered, and acadesine will be added to the priming solution (5 µg/mL) in the heart lung machine during CPB.
Study NCT00872001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline, 500 mL delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 1.2 mL/min for a 500 mL solution. In addition, standard cardioplegia solution with added normal saline will be administered, and placebo (normal saline) will also be added to the heart lung machine priming solution.
Study NCT03471377 — intervention group
Intervention type: OTHER
Intervention: standard scheduling process
Description: Scheduling office assigns start time and room for case and places case on schedule. At this point a default case duration is evaluated by the scheduling office, to see if the value is considered excessively short or excessively long. Depending on the assessment, the scheduling office will either keep the default value, use the value that the surgeon placed in the notes (if available), or the scheduling office provides their own estimation.
Study NCT03471377 — intervention group
Intervention type: OTHER
Intervention: assigned a planned case duration value from predictive model
Description: Predictive model calculates new duration for case at 3AM the day before surgery, and the predictions are made available on a SecureShare-site.~Model predictions are then read by scheduling manager sometime between 7am-10am from the SecureShare site, and the scheduling manager will in EPIC/OpTime, overwrite the current estimate with the new duration value that was generated by the predictive model.
Study NCT04067843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic treatment
Description: Photosensitiser application, followed by fluorescence photography Photodynamic therapy (PHT) (1x) over 15 minutes
Study NCT01453023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate
Description: 100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
Study NCT01453023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol
Description: 100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
Study NCT01354249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: whey protein plus carbohydrate drink
Description: The CHO-P group received 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
Study NCT01354249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein plus carbohydrate drink
Description: The CHO-P group received 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
Study NCT01755676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat 60 mg
Description: 1 tablet 3 times a day
Study NCT01755676 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet 3 times a day
Study NCT05988346 — intervention group
Intervention type: PROCEDURE
Intervention: abdominal plastic intervention
Description: According to international guidelines, authors will remove the superficial abdominal fat from the patients enrolled in the study.
Study NCT04072705 — intervention group
Intervention type: DRUG
Intervention: General principles of care and judgement of researcher
Description: Because our study will be performed by observational design, there will be no intervention for our study. Because it is a registry-based study, overall decision making for medications will be performed according to the general principles of care and judgement of researcher.
Study NCT03091322 — intervention group
Intervention type: DEVICE
Intervention: Pacemaker of the Edora Family (Edora/ Evity/ Enitra/ Enticos) 8
Description: Assessment of the AV Opt and LV VectorOpt features